Trials / Completed
CompletedNCT01129531
A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 294 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of AGN-214868 in patients with postherpetic neuralgia (PHN) - nerve pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-214868 | AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment. |
| DRUG | Placebo to AGN-214868 | Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment. |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2011-10-01
- Completion
- 2012-01-01
- First posted
- 2010-05-24
- Last updated
- 2013-11-15
- Results posted
- 2013-11-15
Locations
4 sites across 4 countries: United States, Czechia, Germany, Poland
Source: ClinicalTrials.gov record NCT01129531. Inclusion in this directory is not an endorsement.